Skip to main content

Table 2 Findings of bronchoalveolar lavage analysis

From: Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer

Case Age Gender Smoking status Site Recovery rate (%) TCC (× 105/mL) AM (%) Lym (%) Neu (%) Eos (%) CD4:CD8
1 68 M Former
2 73 F Never rt. B10 49.0 2.1 52.6 44.8 1.8 0.8 1.5
3 68 M Former rt. middle lobe 59.5 1.6 47.0 46.4 5.8 0.8 0.3
4 66 M Former lt. B5 58.0 2.7 66.4 29.0 1.6 3.0 0.5
5 51 M Current rt. B5 59.0 2.2 5.8 90.4 0.8 3.0 0.5
6 79 M Former lt. B4 49.0 1.3 12.2 86.0 1.4 0.4 0.9
7 70 M Former lt. B8 43.5 2.5 20.4 76.6 1.4 1.6 3.6
8 74 M Former rt. B3 17.5 0.4 32.2 47.8 15.6 4.4 0.5
9 72 M Former
10 71 M Former rt. B4 57.0 3.5 54.0 30.0 14.0 2.0 0.1
11 63 F Never rt. B4 70.2 2.3 16.2 64.2 0.4 19.2 0.5
12 70 F Never rt. B2 41.5 1.2 78.8 20.4 0.4 0.4 0.5
  1. Cases 1–5, 7, 8, 12: adenocarcinoma; Cases 6, 9, 11: squamous cell carcinoma; Case 10: not otherwise specified
  2. AM, alveolar macrophage; CD, cluster of differentiation; Eos, eosinophils; Lym, lymphocytes; Neu, neutrophils; TCC, total cell count